Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of bortezomib-based induction and maintenance versus vincristine/thalidomide-based intensive therapy in untreated multiple myeloma
2004-000944-26Phase 3Completed
- Sponsor
- HOVON
- Start
- May 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bortezomib, doxorubicin, dexamethasone, vincristine, thalidomide and 2 more in multiple myeloma (MM) (2 arms), sponsored by HOVON. Primary endpoint: Progression-free survival. Started May 2007; status: completed.
02
Drugs
bortezomibdoxorubicindexamethasonevincristinethalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2004-000944-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000944-26.